Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Houston Law Firm Brewer & Pritchard, P.C., Warns Consumers about Possible Dangerous Side Effects Tied to Anticoagulant Drug Xarelto
  • USA - English


News provided by

Big Voodoo Interactive

Aug 11, 2014, 17:00 ET

Share this article

Share toX

Share this article

Share toX


Houston, TX (PRWEB) August 11, 2014 -- Drug manufacturer Bayer AG faces lawsuits in the United States for its blood-thinning drug Xarelto along with Johnson & Johnson, which markets Xarelto in the United States, according to news reports. Houston lawyer J. Mark Brewer of Brewer & Pritchard, P.C., understands that the FDA changed the boxed warning on the drug to alert consumers of the bleeding risk.

Brewer based his comments on several articles about legal action taken against Xarelto in the United States, including an article published by Reuters on June 14.

Serious health issues linked to powerful drugs call for action by consumers who are affected.

Post this

“Serious health issues linked to powerful drugs call for action by consumers who are affected,” Brewer said today. “Even though drugs like Xarelto undergo rigorous testing by the Food and Drug Administration (FDA) in the United States, the testing is limited to a finite number of patients. Thus, when the drug finally reaches the market and the general population, many consumers experience serious side effects after being exposed to certain medications. In extreme cases, some people also have died due to adverse health problems caused by drugs designed to make them better. That’s why it’s important for injury victims and their families to be aware of the risks and to understand their rights if they develop serious health problems after using Xarelto or another drug.”

An unidentified person in the United States filed the lawsuit against Germany’s Bayer AG for its anti-blood clotting drug Xarelto, according to Reuters, which cited Frankfurter Allgemeine Zeitung newspaper in Germany.

In the first quarter of 2013, the number of reported adverse events associated with Xarelto (680) surpassed Pradaxa (528), another new oral anticoagulant, which had previously ranked as the number one reported drug for adverse events in 2012, according to a May 7 analysis of the statistics by the Institute of Safe Medication Practices (ISMP).

Due to the increase in possible adverse side effects, the U.S. Food and Drug Administration (FDA) changed its boxed warning on Xarelto in March 2014. Potential adverse side effects of Xarelto include bleeding, according to the FDA. The FDA also noted that no antidote exists to reverse potential side effects associated with Xarelto.

Such possible health risks associated by Xarelto must be taken seriously by patients, according to Texas product liability lawyer J. Mark Brewer of Brewer & Pritchard, P.C.

“We understand that many people are reluctant to contact an attorney when they’re dealing with a health crisis like potentially dangerous side effects from Xarelto,” Brewer said. “But there’s a legitimate reason why many families choose to file a lawsuit to resolve such complicated issues. The problem is many drug manufacturers and their insurance companies simply fail to offer injury victims enough money to cover the true cost of their health-related problems. It’s not just medical expenses people need to consider. It’s the loss of income from not being able to work, the decrease in someone’s quality of life and even sometimes how long they will live. All of these factors need to be taken into consideration. That’s why we strongly urge families to explore their legal options if they’re suffering from serious side effects caused by any medication.”

For more information about legal options for consumers, call 800-445-8710 or complete the online contact form.

The Reuters article cited is “Bayer faces law suits in United States over Xarelto: paper,” June 14, 2014)

The ISMP report cited is “Quarter Watch: Monitoring FDA MedWatch Reports: Perspective on Drug Hyper Sensitivity: Executive Summary.”

About Brewer & Pritchard, P.C.

Serving clients throughout Texas and across the country, the attorneys at Brewer & Pritchard, P.C. have a well-earned reputation for being knowledgeable, experienced lawyers focused on results. The Houston law firm handles a wide variety of cases, including Medicaid fraud, whistleblower claims, business law, corporate law, mergers, acquisitions and other legal issues. Our law firm discreetly investigates every case and respects our clients’ privacy. Not certified by the Texas Board of Legal Specialization.

Brewer & Pritchard, P.C.
3 Riverway #1800
Houston, Texas 77056
713-209-2950
http://www.bplaw.com/

Jacob M Del Hagen, Big Voodoo Interactive, http://www.bigvoodoo.com, +1 (413) 650-0593, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.